APLS Q3 2025 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$459M+133.0% YoY

Gross Profit

$434M94.7% margin

Operating Income

$223M48.7% margin

Net Income

$216M47.0% margin

EPS (Diluted)

$1.71

QoQ Revenue Growth

+156.9%

Cash Flow

Operating Cash Flow

$108M

Free Cash Flow

$108M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$658M

Stockholders' Equity

$401M

Cash & Equivalents

$479M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$459M	$197M	+133.0%
Gross Profit	$434M	$163M	+165.8%
Operating Income	$223M	-$47M	+572.0%
Net Income	$216M	-$57M	+475.5%

Revenue Segments

Licensing And Other Revenue

$281M61%

Product

$178M39%